<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 1, 2019 (HealthDay News) — Liquid meal replacements in weight loss diets lead to modest reductions in cardiometabolic risk factors for overweight and obese patients with type 2 diabetes, according to a review published online March 28 in Diabetes Care<\/i>.<\/p>\n
Jarvis C. Noronha, from St. Michael’s Hospital in Toronto, and colleagues conducted a systematic literature review of randomized trials of two weeks or longer assessing the effect of liquid meal replacements versus traditional weight loss diets on cardiometabolic risk factors in overweight\/obese patients with type 2 diabetes. The authors included nine studies with 961 patients.<\/p>\n
The researchers found mean differences for body weight \u22122.37 kg, body mass index \u22120.87 kg\/m\u00b2, body fat \u22121.66 percent, waist circumference \u22122.24 cm, hemoglobin A1c \u22120.43 percent, fasting glucose \u22120.63 mmol\/L, fasting insulin \u221211.83 pmol\/L, systolic blood pressure \u22124.97 mm Hg, and diastolic blood pressure \u22121.98 mm Hg. No effect was seen for meal replacement on blood lipids. Because of imprecision and\/or inconsistency, the overall certainty of the evidence was low to moderate.<\/p>\n
“More high-quality randomized controlled trials investigating the effect of liquid meal replacements as part of a weight loss diet on cardiometabolic risk factors are needed to address the uncertainties and assess whether there are differences among different types of liquid meal replacements,” the authors write.<\/p>\n
Several authors disclosed financial ties to the food and pharmaceutical industries.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n